{"id":"dasabuvir-8-weeks","safety":{"commonSideEffects":["fatigue","nausea","headache"],"contraindications":["severe hepatic impairment"]},"_chembl":null,"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"HCV NS5B RNA-dependent RNA polymerase","explanation":"Dasabuvir binds to a non-nucleoside site on the HCV NS5B polymerase, causing a conformational change that prevents the enzyme from synthesizing viral RNA. This direct-acting antiviral mechanism stops HCV replication without requiring host immune activation.","oneSentence":"Dasabuvir inhibits the HCV NS5B RNA-dependent RNA polymerase, blocking viral RNA replication."},"_scrapedAt":"2026-03-28T03:10:00.999Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779122860,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"sofosbuvir","brand":"Sovaldi","company":"Gilead Sciences","rationale":"Direct-acting antiviral for HCV with pan-genotypic activity"},{"name":"glecaprevir/pibrentasvir","brand":"Mavyret","company":"AbbVie","rationale":"8-week HCV regimen for treatment-naive patients"},{"name":"ledipasvir/sofosbuvir","brand":"Harvoni","company":"Gilead Sciences","rationale":"Fixed-dose combination DAA for HCV treatment"}],"description":"Dasabuvir is a non-nucleoside inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. The 8-week treatment duration represents a shortened regimen being investigated for chronic hepatitis C infection, potentially offering reduced treatment burden compared to standard 12-week courses.","indications":{"approved":[{"status":"investigational","condition":"Chronic hepatitis C virus infection","patientPopulation":"Adults, investigational 8-week duration"}]},"trialDetails":[{"nctId":"NCT02634008","phase":"PHASE3","title":"Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2016-06","conditions":"Hepatitis C, Acute","enrollment":83},{"nctId":"NCT02486406","phase":"PHASE2, PHASE3","title":"A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10-28","conditions":"Chronic Hepatitis C Infection","enrollment":64},{"nctId":"NCT02582632","phase":"PHASE3","title":"A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-11-24","conditions":"Hepatitis C Infection, Hepatitis C Virus","enrollment":166},{"nctId":"NCT01995071","phase":"PHASE2","title":"A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-11","conditions":"Chronic Hepatitis C, Hepatitis C Virus, Compensated Cirrhosis","enrollment":89},{"nctId":"NCT02734173","phase":"PHASE4","title":"Pilot HCV Direct Acting Antiviral Therapy and Metabolism","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2015-07","conditions":"Hepatitis C","enrollment":24},{"nctId":"NCT02618928","phase":"","title":"The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in France","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12-15","conditions":"Chronic Hepatitis C","enrollment":735},{"nctId":"NCT01854528","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-06","conditions":"Chronic Hepatitis C Infection","enrollment":148},{"nctId":"NCT01854697","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-03","conditions":"Chronic Hepatitis C Infection","enrollment":311},{"nctId":"NCT03122132","phase":"","title":"Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r+Dasabuvir 8 Weeks","status":"COMPLETED","sponsor":"Hepa C","startDate":"2017-02-20","conditions":"Hepatitis C Infection","enrollment":200},{"nctId":"NCT01464827","phase":"PHASE2","title":"ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-10","conditions":"Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1","enrollment":580}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["exviera"],"phase":"phase_2","status":"active","brandName":"dasabuvir 8 weeks","genericName":"dasabuvir 8 weeks","companyName":"Hepa C","companyId":"hepa-c","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}